Achillion Pharmaceuticals has announced that the US Food and Drug Administration (FDA) have decided not to lift its clinical hold on sovaprevir, the company’s experimental treatment for the hepatitis C virus. Read our coverage on the story here:
Achillion’s hep C drug remains in limbo - Hepatitis C Trust
Achillion’s hep C drug remains in limbo
Written by
Hep_C_News_team
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
Moderation team
sam_hepctrustPartner